Firms are bringing in new ideas to attract investors, and emerging research and advanced therapies have shown favorable use of digital therapeutics for digital diagnosis and treatment.
Fremont, CA: Today, patients have become more enabled with healthcare becoming more digital. As such, digital health tools are critical to keep up with the growing number of patients involved in the treatment process.
Digital health comprises of many platforms and systems that use technological solutions to enhance healthcare delivery. Digital therapeutics (DTx) is a digital health solution that provides evidence-based software-driven therapeutic interventions to stop and handle diseases. This solution is gradually being adopted by patients and healthcare providers.
Digital therapeutics can provide a solution to unmet patient demands that traditional treatment and therapies have not been able to provide. Companies incorporating life sciences technology to address these gaps, along with quick product development timelines, can greatly benefit standard life sciences companies.
Digital therapeutics in pharmaceutical and medtech companies can help distinguish products with low capital investments in relation to R&D costs of a drug or medical device. It also provides the opportunity to broaden product life cycles, distinguish products in development, and fill the traditional medicine market gaps.
Digital therapeutics’ capabilities have encouraged businesses across industries to explore innovative options. Firms are bringing in new ideas to attract investors, and emerging research and advanced therapies have shown favorable use of digital therapeutics for digital diagnosis and treatment.
Digital therapeutics is set to change medicine’s importance on physically-dosed treatment approaches to end-to-end disease management formed upon behavioral change. Non-traditional competitors, pharmaceuticals, biopharma, and medtech firms can collaborate their healthcare expertise with software technology skills to transform the healthcare sector and capitalize on digital therapeutics’ growth potential.
